Inhibiting Microbial CutC Enzymes to Reduce TMAO
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies to reduce trimethylamine (TMA) and trimethylamine N-oxide (TMAO) levels, associated with cardiovascular and renal diseases, face challenges such as side effects from inhibiting FMO3 enzymes and undesirable effects from reducing choline or L-carnitine intake, which are essential nutrients.
Innovation Solution
Administering therapeutically effective amounts of specific compounds, such as 2-Ethyl-1-butanol and N-Methylglutamic acid, to inhibit CutC and CntA enzymes in Firmicutes and Proteobacteria microorganisms, which are involved in TMA and TMAO production, thereby reducing TMAO levels without affecting human enzyme activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If FMO3 enzyme is inhibited to reduce TMAO levels, then TMAO levels decrease, but hepatic inflammation and trimethylaminuria occur
Solution Approach 1:
The patent extracts the harmful TMAO production pathway by specifically targeting and inhibiting the microbial CutC/CutD complex enzyme system, separating this microbial pathway from the human FMO3 enzyme system. This allows selective reduction of TMAO without affecting human metabolic pathways that would cause side effects.
Solution Approach 2:
The patent introduces microbial enzymes (CutC/CutD complex) as intermediary targets rather than directly inhibiting the human FMO3 enzyme. By acting on the microbial pathway that produces TMA from choline, the treatment indirectly reduces TMAO formation without blocking the human FMO3 enzyme, thus avoiding hepatic inflammation and trimethylaminuria.
2Quantity of substance
If choline or L-carnitine intake is reduced to lower TMA production, then TMA and TMAO levels decrease, but essential nutrient deficiency occurs
Solution Approach 1:
The patent extracts and targets specifically the microbial enzymatic pathway (CutC/CutD complex) responsible for converting choline to TMA, while leaving the human choline metabolism pathway intact. This allows choline to continue serving its essential nutritional functions in human cells while preventing its conversion to harmful TMA by gut bacteria.
Solution Approach 2:
The patent applies local quality by creating selective inhibition that acts differently in different biological compartments: in human cells, choline metabolism continues normally for essential functions, while in microbial cells, the CutC/CutD complex is specifically inhibited to prevent TMA production. This spatial and functional differentiation resolves the contradiction between nutrient availability and TMA reduction.
3Quantity of substance
If CutC and CntA enzymes are selectively inhibited in microorganisms, then TMAO levels decrease without side effects, but specificity in enzyme targeting must be maintained
Solution Approach 1:
The patent segments the TMAO production pathway into distinct microbial and human components, targeting only the microbial segment (CutC/CutD complex and CntA/B enzymes) while leaving the human segment (FMO3 enzyme) untouched. This segmentation enables selective inhibition that reduces TMAO without affecting human metabolism.
Solution Approach 2:
The patent uses microbial enzymes as intermediary targets between choline intake and TMAO formation. By inhibiting the microbial CutC/CutD complex and CntA/B enzymes that act as intermediaries in TMA production, the treatment reduces TMAO levels while maintaining human enzyme function and avoiding direct side effects from FMO3 inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively decreases TMAO levels, reducing the risk of cardiovascular and renal diseases while minimizing side effects by selectively targeting microbial enzymes, thus providing a safer therapeutic option.
Implementation Method 1
the trimethylamine-lyase (CutC) enzyme, which is a glycine radical enzyme that performs the cleavage of the C—N bond in choline to produce trimethylamine (TMA) and acetaldehyde
Implementation Method 2
TMA metabolite, which is often obtained from meat, egg (e.g., egg yolk, etc.), fat-rich food, and/or dairy products is absorbed and converted to TMAO in the liver by the action of the human. Flavin-containing monooxygenase 3 (FMO3) enzyme.
Implementation Method 3
the other one using L-carnitine (the two-component Rieske-type oxygenase/reductase CntA/B)
Data Source
AI summary
Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.